Mr. James Parsons reports
TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
Trillium Therapeutics Inc. has provided the voting results from its annual and special meeting of shareholders held on June 27, 2019. The results of the director elections were as displayed in the table.
% votes in Votes % votes
Name Votes in favour favour withheld withheld
Luke Beshar 5,579,317 85 977,217 15
Dr. Robert Kirkman 5,614,544 85 941,990 15
Dr. Michael Moore 5,586,552 85 969,982 15
Dr. Thomas Reynolds 5,580,252 85 976,282 15
Dr. Robert Uger 5,615,550 86 940,984 14
Dr. Calvin Stiller 5,581,832 85 974,702 15
Dr. Helen Tayton-Martin 5,687,094 87 869,440 13
The shareholders of the corporation also voted to reappoint Ernst & Young LLP, chartered professional accountants, licensed public accountants as auditors of the corporation for the ensuing year. In addition, the shareholders approved the special resolutions to continue the corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act and the potential consolidation of the corporation's issued and outstanding common shares.
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.
© 2020 Canjex Publishing Ltd. All rights reserved.